Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Medicenna Therapeutics Corp (MDNA.TO)

Medicenna Therapeutics Corp (MDNA.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 173,397
  • Shares Outstanding, K 69,637
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,048 K
  • 60-Month Beta 2.84
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.31
Trade MDNA.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.23
  • Most Recent Earnings $-0.07 on N/A
  • Latest Earnings Date 02/20/24
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.07
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.07
  • Prior Year -0.06
  • Growth Rate Est. (year over year) -16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.40 +65.71%
on 04/09/24
2.68 -13.43%
on 04/29/24
+0.46 (+24.73%)
since 03/28/24
3-Month
0.41 +465.85%
on 01/31/24
2.68 -13.43%
on 04/29/24
+1.90 (+452.38%)
since 01/29/24
52-Week
0.22 +979.07%
on 11/01/23
2.68 -13.43%
on 04/29/24
+1.42 (+157.78%)
since 04/28/23

Most Recent Stories

More News
Stocks in play: Medicenna Therapeutics Corp.

Presented updated clinical results from the monotherapy dose escalation and ongoing expansion portions ...

MDNA.TO : 2.35 (-5.62%)
Stocks in play: Medicenna Therapeutics Corp

Announced that CEO Dr. Fahar Merchant, President and CEO will present and participate in one-on-one ...

MDNA.TO : 2.35 (-5.62%)
Stocks in play: Medicenna Therapeutics Corp

Announced today that two posters will be presented at the American Association for Cancer Research Annual ...

MDNA.TO : 2.35 (-5.62%)
Stocks in play: Medicenna Therapeutics Corp.

Today announced the first patient dosed in the combination arm of the Phase 1/2 ABILITY (ABeta-only ...

MDNA.TO : 2.35 (-5.62%)
Stocks in play: Medicenna Therapeutics Corp.

Today announced initiation of enrollment in the combination arm of the Phase 1/2 ABILITY (ABeta-only ...

MDNA.TO : 2.35 (-5.62%)
Stocks in play: Medicenna Therapeutics Corp.

Announced that a poster presentation and an oral summary highlighting longer term follow up results ...

MDNA.TO : 2.35 (-5.62%)
Stocks in play: Medicenna Therapeutics Corp.

Received a Staff Delisting Determination from the Listing Qualifications Department of the NASDAQ Stock ...

MDNA.TO : 2.35 (-5.62%)
Stocks in play: Medicenna Therapeutics Corp.

Today announced dosing of the first patient in the Phase 2 monotherapy dose expansion portion of the ...

MDNA.TO : 2.35 (-5.62%)
Stocks in play: Medicenna Therapeutics Corp.

Announced the appointment of Humphrey Gardner, M.D., as Chief Medical Officer (CMO) to lead the development ...

MDNA.TO : 2.35 (-5.62%)
Stocks in play: Medicenna Therapeutics Corp.

Will present preclinical results featuring its MDNA223 BiSKIT candidate at the 2023 AACR Special Conference ...

MDNA.TO : 2.35 (-5.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent...

See More

Key Turning Points

3rd Resistance Point 3.24
2nd Resistance Point 2.93
1st Resistance Point 2.71
Last Price 2.35
1st Support Level 2.18
2nd Support Level 1.87
3rd Support Level 1.65

See More

52-Week High 2.68
Last Price 2.35
Fibonacci 61.8% 1.74
Fibonacci 50% 1.45
Fibonacci 38.2% 1.16
52-Week Low 0.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar